H.C. Wainwright assumed coverage of Acurx (ACXP) with a Buy rating and $8 price target Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria, the analyst tells investors in a research note. The firm believes the company is “flying under the radar with investors” into a “paradigm shifting moment in anti-infectives.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACXP:
- Acurx Pharmaceuticals: Promising Antibiotic Developments and Strong Financial Position Justify Buy Rating
- Acurx Pharmaceuticals Reports Improved Q1 2025 Results
- Acurx Pharmaceuticals Enters $12M Stock Purchase Agreement
- Acurx granted new patent for DNA Polymerase IIIC Inhibitors
- Acurx files to sell 8.4M shares of common stock for holders